Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Trial to Evaluate the Safety and Feasibility of CK0801 in Treatment of Bone Marrow Failure Syndrome

Trial Profile

Phase I Trial to Evaluate the Safety and Feasibility of CK0801 in Treatment of Bone Marrow Failure Syndrome

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs CK 0801 (Primary)
  • Indications Aplastic anaemia; Bone marrow disorders; Myelodysplastic syndromes; Myelofibrosis
  • Focus Adverse reactions
  • Sponsors Cellenkos
  • Most Recent Events

    • 10 Dec 2018 Status changed from planning to not yet recruiting.
    • 24 Oct 2018 New trial record
    • 16 Oct 2018 According to a Cellenkos media release, the company holds an approved FDA IND to proceed with this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top